Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to
compare the efficacy, safety and tolerability of NN1250 (insulin degludec ([Deg]) with
insulin detemir (IDet), both combined with insulin aspart.
The main period is registered internally at Novo Nordisk as NN1250-3585 while the extension
period is registered as NN1250-3725.